Genome Editing
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
Sangamo Therapeutics
PR-M02-19-NI-020Feb 11, 2019
Preliminary Data
Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913
Sangamo Therapeutics
PR-M08-18-NI-027Aug 08, 2018